Tóth Noémi Klára, Csanádi Zoltán, Hajas Orsolya, Kiss Alexandra, Nagy-Baló Edina, Kovács Kitti Bernadett, Sarkady Ferenc, Muszbek László, Bereczky Zsuzsanna, Csiba László, Bagoly Zsuzsa
Division of Clinical Laboratory Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Institute of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Biomed Res Int. 2017;2017:3678017. doi: 10.1155/2017/3678017. Epub 2017 Jun 21.
To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associated with atrial fibrillation (AF) and increase the risk of thromboembolism.
Patient group consisted of 24 patients with AF and control group included 14 individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), plasminogen, -plasmin inhibitor, plasmin--antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were measured from all samples.
Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure.
None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage, presenting at both intracardiac and systemic level.
识别与心房颤动(AF)相关且增加血栓栓塞风险的心脏内止血或纤维蛋白溶解异常。
患者组由24例房颤患者组成,对照组包括14例接受经导管射频消融的其他室上性心动过速患者。在消融术前从股静脉(FV)、左心房(LA)和左心耳(LAA)采集血样。检测所有样本中的纤维蛋白原、凝血因子VIII(FVIII)和凝血因子XIII活性、血管性血友病因子(VWF)抗原、凝血酶 - 抗凝血酶(TAT)复合物、定量纤维蛋白单体(FM)、纤溶酶原、α-纤溶酶抑制剂、纤溶酶 - α-抗纤溶酶(PAP)复合物、PAI - 1活性和D - 二聚体。
与对照组相比,房颤患者FV和LA中的FVIII和VWF水平显著升高。在两组中,LA中的TAT复合物、FM, PAP复合物和D二聚体水平均显著高于FV样本,表明与导管插入术相关的临时血栓形成风险。
与非房颤对照组相比,房颤患者中所研究的止血或纤维蛋白溶解参数均未显示出明显的心脏内改变。房颤患者FVIII和VWF水平升高,很可能是由于内皮损伤,在心脏内和全身水平均有表现。